Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase

Yunpeng Bai, Zhi Hong Yu, Sijiu Liu, Lujuan Zhang, Ruo Yu Zhang, Li Fan Zeng, Sheng Zhang, Zhong-Yin Zhang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Phosphatase of regenerating liver (PRL) oncoproteins are phosphatases overexpressed in numerous types of human cancer. Elevated levels of PRL associate with metastasis and poor clinical outcomes. In principle, PRL phosphatases offer appealing therapeutic targets, but they remain underexplored due to the lack of specific chemical probes. In this study, we address this issue by exploiting a unique property of PRL phosphatases, namely, that they may function as homotrimers. Starting from a sequential structure-based virtual screening and medicinal chemistry strategy, we identified Cmpd-43 and several analogs that disrupt PRL1 trimerization. Biochemical and structural analyses demonstrate that Cmpd-43 and its close analogs directly bind the PRL1 trimer interface and obstruct PRL1 trimerization. Cmpd-43 also specifically blocks the PRL1-induced cell proliferation and migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exerted potent anticancer activity both in vitro and in vivo in a murine xenograft model of melanoma. Our results validate a trimerization-dependent signaling mechanism for PRL and offer proof of concept for trimerization inhibitors as candidate therapeutics to treat PRL-driven cancers.

Original languageEnglish (US)
Pages (from-to)4805-4815
Number of pages11
JournalCancer Research
Volume76
Issue number16
DOIs
StatePublished - Aug 15 2016

Fingerprint

Phosphoric Monoester Hydrolases
Antineoplastic Agents
Liver
Pharmaceutical Chemistry
Oncogene Proteins
Liver Neoplasms
Heterografts
Cell Movement
Melanoma
Cell Proliferation
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. / Bai, Yunpeng; Yu, Zhi Hong; Liu, Sijiu; Zhang, Lujuan; Zhang, Ruo Yu; Zeng, Li Fan; Zhang, Sheng; Zhang, Zhong-Yin.

In: Cancer Research, Vol. 76, No. 16, 15.08.2016, p. 4805-4815.

Research output: Contribution to journalArticle

Bai, Y, Yu, ZH, Liu, S, Zhang, L, Zhang, RY, Zeng, LF, Zhang, S & Zhang, Z-Y 2016, 'Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase', Cancer Research, vol. 76, no. 16, pp. 4805-4815. https://doi.org/10.1158/0008-5472.CAN-15-2323
Bai, Yunpeng ; Yu, Zhi Hong ; Liu, Sijiu ; Zhang, Lujuan ; Zhang, Ruo Yu ; Zeng, Li Fan ; Zhang, Sheng ; Zhang, Zhong-Yin. / Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. In: Cancer Research. 2016 ; Vol. 76, No. 16. pp. 4805-4815.
@article{c6c8984305c748979b4ab34f924b7bda,
title = "Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase",
abstract = "Phosphatase of regenerating liver (PRL) oncoproteins are phosphatases overexpressed in numerous types of human cancer. Elevated levels of PRL associate with metastasis and poor clinical outcomes. In principle, PRL phosphatases offer appealing therapeutic targets, but they remain underexplored due to the lack of specific chemical probes. In this study, we address this issue by exploiting a unique property of PRL phosphatases, namely, that they may function as homotrimers. Starting from a sequential structure-based virtual screening and medicinal chemistry strategy, we identified Cmpd-43 and several analogs that disrupt PRL1 trimerization. Biochemical and structural analyses demonstrate that Cmpd-43 and its close analogs directly bind the PRL1 trimer interface and obstruct PRL1 trimerization. Cmpd-43 also specifically blocks the PRL1-induced cell proliferation and migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exerted potent anticancer activity both in vitro and in vivo in a murine xenograft model of melanoma. Our results validate a trimerization-dependent signaling mechanism for PRL and offer proof of concept for trimerization inhibitors as candidate therapeutics to treat PRL-driven cancers.",
author = "Yunpeng Bai and Yu, {Zhi Hong} and Sijiu Liu and Lujuan Zhang and Zhang, {Ruo Yu} and Zeng, {Li Fan} and Sheng Zhang and Zhong-Yin Zhang",
year = "2016",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-15-2323",
language = "English (US)",
volume = "76",
pages = "4805--4815",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase

AU - Bai, Yunpeng

AU - Yu, Zhi Hong

AU - Liu, Sijiu

AU - Zhang, Lujuan

AU - Zhang, Ruo Yu

AU - Zeng, Li Fan

AU - Zhang, Sheng

AU - Zhang, Zhong-Yin

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Phosphatase of regenerating liver (PRL) oncoproteins are phosphatases overexpressed in numerous types of human cancer. Elevated levels of PRL associate with metastasis and poor clinical outcomes. In principle, PRL phosphatases offer appealing therapeutic targets, but they remain underexplored due to the lack of specific chemical probes. In this study, we address this issue by exploiting a unique property of PRL phosphatases, namely, that they may function as homotrimers. Starting from a sequential structure-based virtual screening and medicinal chemistry strategy, we identified Cmpd-43 and several analogs that disrupt PRL1 trimerization. Biochemical and structural analyses demonstrate that Cmpd-43 and its close analogs directly bind the PRL1 trimer interface and obstruct PRL1 trimerization. Cmpd-43 also specifically blocks the PRL1-induced cell proliferation and migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exerted potent anticancer activity both in vitro and in vivo in a murine xenograft model of melanoma. Our results validate a trimerization-dependent signaling mechanism for PRL and offer proof of concept for trimerization inhibitors as candidate therapeutics to treat PRL-driven cancers.

AB - Phosphatase of regenerating liver (PRL) oncoproteins are phosphatases overexpressed in numerous types of human cancer. Elevated levels of PRL associate with metastasis and poor clinical outcomes. In principle, PRL phosphatases offer appealing therapeutic targets, but they remain underexplored due to the lack of specific chemical probes. In this study, we address this issue by exploiting a unique property of PRL phosphatases, namely, that they may function as homotrimers. Starting from a sequential structure-based virtual screening and medicinal chemistry strategy, we identified Cmpd-43 and several analogs that disrupt PRL1 trimerization. Biochemical and structural analyses demonstrate that Cmpd-43 and its close analogs directly bind the PRL1 trimer interface and obstruct PRL1 trimerization. Cmpd-43 also specifically blocks the PRL1-induced cell proliferation and migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exerted potent anticancer activity both in vitro and in vivo in a murine xenograft model of melanoma. Our results validate a trimerization-dependent signaling mechanism for PRL and offer proof of concept for trimerization inhibitors as candidate therapeutics to treat PRL-driven cancers.

UR - http://www.scopus.com/inward/record.url?scp=84982182373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982182373&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2323

DO - 10.1158/0008-5472.CAN-15-2323

M3 - Article

C2 - 27325652

AN - SCOPUS:84982182373

VL - 76

SP - 4805

EP - 4815

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -